Black Diamond Therapeutics (BDTX) Asset Utilization Ratio (2025)

Black Diamond Therapeutics' (BDTX) quarterly Asset Utilization Ratio came in at 0.47 in Q4 2025, up 7.77% quarter-over-quarter from 0.43 in Q3 2025.

Analysis

Black Diamond Therapeutics (BDTX) Asset Utilization Ratio (2025) Analysis & Trends

Black Diamond Therapeutics (BDTX) has reported Asset Utilization Ratio for 1 consecutive years, with 0.47 the latest figure, recorded in Q4 2025.

For the quarter ending Q4 2025, Asset Utilization Ratio changed N/A year-over-year to 0.47; the trailing twelve-month figure through Dec 2025 stood at 0.47 (changed N/A YoY), and the FY2025 full-year result was 0.53, changed N/A from the prior year.
Asset Utilization Ratio improved to 0.47 in Q4 2025 per BDTX's latest filing, from 0.43 in the prior quarter.
Across five years, Asset Utilization Ratio topped out at 0.47 in Q1 2025 and bottomed at 0.41 in Q2 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn	0.40
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn	0.58
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn	0.47
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn	0.38
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn	-
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn	0.20
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn	0.90
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn	0.33
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn	0.00
10	Black Diamond Therapeutics	111.58 Mn	1.07 Mn	-	-

Historic Data

Download Data